Pharmacological strategies for the prevention of Alzheimer’s disease

Bibliography

• DORAISWAMY PM: Non-cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs (2002) 16:811-824.
   PubMed Web of Science ®Google Scholar
• WINBLAD B, PALMER K, KIVIPELTO et al.: Mild cognitive impairment–beyond controversies, toward a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. (2004) 256:240-246.
   PubMed Web of Science ®Google Scholar
• CELERMAJER DS: Primary and a half prevention: can we identify asymptomatic subjects with high vascular risk? J. Am. Coll. Cardiol. (2005) 45(12):1994-1996.
   PubMed Web of Science ®Google Scholar
• SALLOWAY S, FERRIS S, KLUGER A et al.: Efficacy of donepezil in mild cognitive impairment: a randomized, placebo-controlled trial. Neurology (2004) 63:651-657.
   PubMed Web of Science ®Google Scholar
• PETERSEN RC, THOMAS RG, GRUNDMAN M et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. (2005) 352:2379-2388.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT, MARAGOS WF, ALBIN RL et al.: Glutamate transmission and toxicity in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12:421-430.
   PubMed Web of Science ®Google Scholar
• TOPPER R, GEHRMANN J, BANATI R et al.: Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol. (1995) 89:23-28.
   PubMed Web of Science ®Google Scholar
• SEIF EL NASR M, PERUCHE B, ROSSBERG C et al.: Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol. (1990) 185:19-24.
   PubMed Web of Science ®Google Scholar
• MIGUEL-HIDALGO JJ, ALVAREX XA, CACABELOS R, QUACK G: Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. (2002) 958(1):210-221.
   PubMed Web of Science ®Google Scholar
• AISEN PS, DAVIS KL, BERG JD et al.: A randomized controlled trial of prednisone in Alzheimer’s disease. Neurology (2000) 54:588-593.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, MCGEER EG: Inflammation, autotoxicity and Alzheimer’s disease. Neurobiol. Aging (2001) 22:799-809.
   PubMed Web of Science ®Google Scholar
• ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trial of indomethacin in Alzheimer’s disease. Neurology (1993) 43:1609-1611.
   PubMed Web of Science ®Google Scholar
• SCHARF S, MANDER A, UGONI A et al.: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology (1999) 53:197-201.
   PubMed Web of Science ®Google Scholar
• SAINATI SM, INGRAM DM, TALWALKER S et al.: Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer’s disease. 6th International Stockholm/Springfield Meeting on Advances in Alzheimer Therapy. Stockholm, Sweden (5 – 8 April, 2000).
   Google Scholar
• AISEN PS, SCHAFER KA, GRUNDMAN M et al.: Effects of rofecoxib or naproxen versus placebo on Alzheimer’s disease progression. JAMA (2003) 289:2819-2826.
   PubMed Web of Science ®Google Scholar
• THAL LJ, FERRIS SH, KIRBY L et al.: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology (2005) 30:1204-1215.
   PubMed Web of Science ®Google Scholar
• GASPARINI L, ONGINI E, WILCOCK D, MORGAN D: Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer’s disease. Brain Res. Rev. (2005) 48(2):400-408.
   PubMed Web of Science ®Google Scholar
• OKEN BS, STORZBACH DM, KAYE JA: The efficacy of ginkgo biloba on cognitive function in Alzheimer’s disease. Arch. Neurol. (1998) 55(11):1409-1415.
   PubMed Web of Science ®Google Scholar
• WETTSTEIN A: Cholinesterase inhibitors and ginkgo extracts: Are they comparable in the treatment of dementia? Phytomedicine (2000) 6(6):393-401.
   PubMed Web of Science ®Google Scholar
• STOUGH C, CLARKE J, LLOYD J et al.: Neuropsychological changes after 30-day ginkgo biloba administration in healthy participants. Int. J. Neuropsychopharmacol. (2001) 4:131-134.
   PubMed Web of Science ®Google Scholar
• SOLOMON PR, ADAMS F, SILVER A et al.: Ginkgo for memory enhancement: a randomized controlled trial. JAMA (2002) 288:835-840.
   PubMed Web of Science ®Google Scholar
• DONGEN MV, ROSSUM EV, KESSELS A et al.: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J. Clin. Epid. (2003) 56:367-376.
   PubMed Web of Science ®Google Scholar
• TUSZYNSKI MH, SANG H, YOSHIDA K et al.: Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. (1991) 30:625-636.
   PubMed Web of Science ®Google Scholar
• BAE CY, CHO CY, CHO K et al.: A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer’s disease. J. Am. Geriatr. Soc. (2000) 48(12):1566-1571.
   PubMed Web of Science ®Google Scholar
• PANISSET M, GAUTHIER S, MOESSLER H et al.: Sustained improvement in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of cerebrolysin therapy. J. Neural Transm. (2000) 107:815-829.
   PubMed Web of Science ®Google Scholar
• ROCKENSTEIN E, ADAME A, MANTE M et al.: The neuroprotective effects of cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance. J. Neural Transm. (2003) 110:1313-1327.
   PubMed Web of Science ®Google Scholar
• APPERT-COLLINS A, DUONG FH, PASSILLY DEGRACE P et al.: MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden. Int. J. Immunopathol. Pharmacol. (2005) 18(1):21-31.
   Web of Science ®Google Scholar
• CASSERLY I, TOPOL E: Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet (2004) 363:1139-1146.
   PubMed Web of Science ®Google Scholar
• KOJRO E, GIMPL G, LAMMICH S et al.: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase. Alzheimer’s disease AM 10. Proc. Natl. Acad. Sci. USA (2001) 98:5815-5820.
   PubMed Web of Science ®Google Scholar
• SPARKS DL, KUO YM, ROHER A et al.: Alterations of Alzheimer’s disease in the cholesterol-fed rabbit, including vascular inflammation. Ann. NY Acad. Sci. (2000) 903:335-344.
   PubMed Web of Science ®Google Scholar
• FREARS ER, STEPHENS DJ, WALTERS CE et al.: The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport (1999) 10:1699-1705.
   PubMed Web of Science ®Google Scholar
• SIMONS M, KELLER P, DE STROOPER B et al.: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA (1998) 95:6460-6464.
   PubMed Web of Science ®Google Scholar
• ZANDI PP, SPARKS DL, KHACHATURIAN AS et al.: Do statins reduce risk of incident dementia and Alzheimer’s disease? The Cache County Study. Arch. Gen. Psychiatry (2005) 62:217-224.
   PubMed Web of Science ®Google Scholar
• DORAISWAMY PM, STEFFENS DC, MCQUOID DR: Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer’s disease: a pilot longitudinal study. Am. J. Alzheimers Dis. (2004) 19:275-278.
   Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individual: a randomized placebo-controlled trial. Lancet (2002) 360:7-22.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623-1630.
   PubMed Web of Science ®Google Scholar
• SPARKS DL, SABBAGH MN, CONNOR DJ et al.: Atorvastatin for the treatment of mild to moderate Alzheimer’s disease: preliminary results. Arch. Neur. (2005) 62:753-767.
   Google Scholar
• TORAN-ALLERAND CD, MIRANDA RC, BENTHAM WD et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA (1992) 89:4668-4672.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW: Estrogen, cognition, and a women’s risk of Alzheimer’s disease. Am. J. Med. (1997) 103:1S-2S.
   Google Scholar
• RAPP SR, ESPELAND MA, SHUMAKER SA et al.: Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women’s Health Initiative Memory Study. JAMA (2003) 289:2663-2672.
   PubMed Web of Science ®Google Scholar
• SHUMAKER SA, LEGAULT C, KULLER L et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study. JAMA (2004) 291:2947-2958.
   PubMed Web of Science ®Google Scholar
• WRITING GROUP FOR THE WOMEN’S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA (2002) 288:321-333.
   PubMed Web of Science ®Google Scholar
• YAFFE K, KRUEGER K, CUMMINGS SR et al.: Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the multiple outcomes of raloxifene evaluation (MORE) randomized trial. Am. J. Psychiatry (2005) 162:683-690.
   PubMed Web of Science ®Google Scholar
• MARKESBERY WR, CARNEY JM: Oxidative alteration in Alzheimer’s disease. Brain Pathol. (1999) 9:133-146.
   PubMed Web of Science ®Google Scholar
• PICCININ GL, FINALI G, PICCIRILLI M: Neuropsychological effects of L-deprenyl in Alzheimer’s type dementia. Clin. Neuropharmacol. (1990) 13:147-163.
   PubMed Web of Science ®Google Scholar
• MANGONI A, GRASSI MP, FRATTOLA L et al.: Effects of a MAO-B inhibitor in the treatment of Alzheimer’s disease. Eur. Neurol. (1991) 31:433a.
   Google Scholar
• LONN E, BOSCH J, YUSUF S et al.: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 293:1338-1347.
   PubMed Web of Science ®Google Scholar
• GILMAN S, KOLLER M, BLACK RS et al.: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 64:1553-1562.
   PubMed Web of Science ®Google Scholar
• FOX NC, BLACK RS, GILMAN S et al.: Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer’s disease. Neurology (2005) 64:1563-1572.
   PubMed Web of Science ®Google Scholar
• PRINCE MJ, BIRD AS, BLIZARD RA, MANN AH: Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s treatment trial of hypertension in older adults. Br. Med. J. (1996) 312:801-805.
   PubMed Web of Science ®Google Scholar
• SHEP COOPERATIVE RESEARCH GROUP: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA (1991) 265:3255-3264.
   PubMed Web of Science ®Google Scholar
• FORETTE F, SEUX ML, STAESSEN JA et al.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Sys-Eur) study. Arch. Intern. Med. (2002) 162:2046-2052.
   PubMed Web of Science ®Google Scholar
• THE PROGRESS COLLABORATIVE GROUP: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. (2003) 163:1069-1075.
   PubMed Web of Science ®Google Scholar
• BENEDICT RH: Cognitive function after open-heart surgery: are postoperative neuropsychological deficits caused by cardiopulmonary bypass? Neuropsychol. Rev. (1994) 4(3):223-255.
   PubMed Web of Science ®Google Scholar
• BROWN WR, MOODY DM, TYTELL M et al.: Microembolic brain injuries from cardiac surgery: are they seeds of future Alzheimer’s disease? Ann. NY Acad. Sci. (1997) 826:386-389.
   PubMedGoogle Scholar
• CAPLAN L: Protecting the brains of patients after heart surgery. Arch. Neurol. (2001) 58:549-550.
   PubMedGoogle Scholar
• RAJA PV, BLUMENTHAL JA, DORAISWAMY PM: Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. CNS Spectr. (2004) 9(10):763-772.
   PubMed Web of Science ®Google Scholar